National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure.
نویسندگان
چکیده
I. Overview of Heart Failure. . . . . . . . . . . . . . . . . . . . . . .e99 A. Context of Biochemical Marker Testing in Heart Failure. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .e99 B. Background and Definition of Terms . . . . . . . . . .e100 C. B-type Natriuretic Peptide (BNP) and AminoTerminal proB-Type Natriuretic Peptide (NT-proBNP) Metabolism and Measurement . . . .e100 II. Use of Biochemical Markers in the Initial Evaluation of Heart Failure . . . . . . . . . . . . . . . . . . . .e101 A. Diagnosis of Heart Failure. . . . . . . . . . . . . . . . . . .e101 1. BNP and NT-proBNP for Diagnosis of Acute Decompensated Heart Failure . . . . . . . . . . . . . .e102 2. BNP or NT-proBNP for Confirmation of the Heart Failure Diagnosis. . . . . . . . . . . . . . . . . . .e103 B. Risk Stratification of Heart Failure . . . . . . . . . . . .e103 1. Risk stratification of Patients With and Without Heart Failure Using BNP or NT-proBNP . . . . . . . . . . . . . . . . . . . . . . . . . . . .e103 2. Risk Stratification of Patients With Heart Failure Using Cardiac Troponin . . . . . . . . . . . .e104 III. Use of Biochemical Markers in Screening for Cardiac Dysfunction . . . . . . . . . . . . . . . . . . . . . . . . .e104 A. BNP or NT-proBNP for Screening Heart Failure and Dysfunction . . . . . . . . . . . . . . . . . . .e104 B. Approaches for Screening for Cardiac Dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . . .e104 IV. Use of Biochemical Markers in Guiding Management of Heart Failure. . . . . . . . . . . . . . . . . .e105 A. Monitoring Therapy Using BNP or NT-proBNP Guidance. . . . . . . . . . . . . . . . . . . . .e105 V. References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .e105
منابع مشابه
Unusual findings in hypertension screening: aortic coarctation, double orifice mitral valve, and patent ductus arteriosus.
testing in general populations. Am J Cardiol 2008;101:16–20. 33. Rosenberg J, Schou M, Gustafsson F, Badskjær J, Hildebrandt P. Prognostic threshold levels of NT-proBNP testing in primary care. Eur Heart J 2009;30:66–73. 34. Tang WH, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL, Storrow AB, Christenson RH, Apple FS, Ravkilde J, Wu AH. National Academy of Clinical Biochemistry Laboratory...
متن کاملNational Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure WRITING GROUP MEMBERS
I. Overview of Heart Failure. . . . . . . . . . . . . . . . . . . . . . .e99 A. Context of Biochemical Marker Testing in Heart Failure. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .e99 B. Background and Definition of Terms . . . . . . . . . .e100 C. B-type Natriuretic Peptide (BNP) and AminoTerminal proB-Type Natriuretic Peptide (NT-proBNP) Metabolism and Measurement . . . .e100 I...
متن کاملNational Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes.
I. OVERVIEW OF ANALYTICAL ISSUES FOR ACUTE CORONARY SYNDROME (ACS) BIOMARKERS ............................................................548 A. Analytical Issues: Background ..........................548 II. ANALYTICAL BIOMARKER ISSUES....................548 A. Cardiac Troponin Specifications .......................548 B. Cardiac Biomarker Turnaround........................549 C. Biomarkers No...
متن کاملNational Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Utilization of Biochemical Markers in Acute Coronary Syndromes and Heart Failure.
Preamble The National Academy of Clinical Biochemistry’s (NACB) Laboratory Medicine Practice Guidelines (LMPG) for use of cardiac markers in coronary artery diseases were published in July 19991. Since production of this initial document, numerous published studies and presented data have added significantly to the knowledge base for biochemical markers of cardiac injury. This increased knowled...
متن کاملSupportive Data for Galectin-3 as a Prognostic Factor in Coronary Artery Disease
Introduction: Galectin-3 is known as a biomarker in patients with heart failure. This protein participates in different mechanisms involved in atherosclerosis including inflammation and plaque formation. This study was conducted to investigate whether this factor could be a predictive biomarker for the severity of atherosclerosis. Materials and Methods: The study group consisted of 80 patients ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Circulation
دوره 116 5 شماره
صفحات -
تاریخ انتشار 2007